The national drugs controller on Tuesday, April 26, 2022 cleared Corbevax for the vaccination of children against Coronavirus belonging to the age group of 5-12 years old.

Corbevax developed by Hyderabad based Biological E. Limited is being presented as  a “recombinant protein sub-unit” vaccine, which means it is made up of a specific part of SARS-CoV-2, that is, the spike protein on the virus’s surface.

The spike protein allows the virus to penetrate cells and create disease-like symptoms. However, unlike being infected with the entire live virus it is not as harmful as the main body(of the virus)  is missing, and the specimen comparatively weakened. The desired result is to coerce the body into developing an immune response against the weakened virus, in turn making the body adapt to fight off the virus and create a response mechanism, should the person be infected anytime in the future. Thus, making it highly unlikely for the  virus to make the victim fall seriously ill.

The technology and approach behind this method itself is not new and has been used for decades to make vaccines for diseases like hepatitis B. However, Corbevax is among the first Covid-19 vaccines to use this platform to fight off against the Coronoavirus.

The vaccine is being hailed as standing up to the mark in providing the requirements and suitability needed for boosting the immuno-response system of the minor population. The vaccine is expected to be made available soon as the roll out modalities are finalised.